Lexeo Therapeutics Cuts Arrhythmia Burden by 80% in Genetic Heart Disease Study
Lexeo Therapeutics reports an 80% mean arrhythmia reduction in its Phase 1/2 LX2020 heart trial and targets a pivotal trial in late 2027.
Last updated: 2026-11-19 07:27:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Lexeo Therapeutics, Inc. (LXEO) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2.94, with a market capitalization of $236.36M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.55 to $10.99. This page covers its latest market performance, valuation, price trends and company information.
$236.36M | |
$2.80 | |
$3.09 | |
$2.76 | |
$2.86 | |
1.64M | |
1.97M | |
-- | |
$10.99 | |
$2.55 | |
-- | |
2026-09-30 |
Lexeo Therapeutics, Inc. (LXEO) last closed at $2.94 as of 2026-11-19 01:00:00, up 2.63% ($0.08) from the previous close of $2.86.
During the latest regular trading session, LXEO traded between $2.76 and $3.09, with a volume of 1.64M shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Lexeo Therapeutics, Inc. (LXEO) moved from $3.06 to $2.94, representing a decline of 4.08% ($0.13).
The stock traded between $2.76 and $4.30 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 6.71 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 4.6%
LXEO is currently trading at $2.94, placing it 4.6% of the way from its 52-week low of $2.55 to its 52-week high of $10.99. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 59 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Lexeo Therapeutics, Inc. and LXEO stock.
Lexeo Therapeutics reports an 80% mean arrhythmia reduction in its Phase 1/2 LX2020 heart trial and targets a pivotal trial in late 2027.
Cantor Fitzgerald analyst Kristen Kluska maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Overweight and raises the price target from $23 to $37.
Across ten participants, including nine with at least 12 months of follow-up, treatment with LX2020 was generally well tolerated and associated with clinically meaningful reductions in arrhythmia burden, including
Gainers Akanda (NASDAQ:AKAN) shares increased by 55.1% to $2.11 during Monday's pre-market session. The market value of their outstanding shares is at $3.5 million. Alpha Tau Medical (NASDAQ:DRTS) stock rose
Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.33) by 30.3 percent. This is a 30.3 percent decrease over losses of $(0.33) per share
Eligible investors can buy real shares of Lexeo Therapeutics, Inc. (LXEO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to LXEO, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between LXEO shares and USD.
LXEO Shares to USD
1.00 LXEO shares = 2.935 USD
Calculations are estimates based on the latest available price and are for reference only.